Keywords: ephalon, Ception, Cinquil, M&A, Research, Asthma
Cephalon exercises option to acquire Ception Therapeutics for $250 million, after successful Cinquil trial
Article | 24 February 2010
Pennsylvania, USA-based Cephalon, says that it has exercised its option to acquire Ception Therapeutics, following receipt of positive data from ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
